---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000072"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:03:42.121950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics announces up to $100M private placement and board changes

## Summary
- Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
- Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.
- Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.
- Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.
- Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others.

## SEC filing metadata
- accession: 0001736730-25-000072
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/camp-20250909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000072
- JSON: https://secwatch.observer/filing/0001736730-25-000072.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000072.txt

## Key facts
- Equity Issuances
  Camp4 Therapeutics Corp issued 26,681,053 shares of common stock to certain accredited investors for $1.53 per Share.
  - Security: common stock
  - Shares: 26,681,053 shares
  - Purchaser: certain accredited investors
  - Consideration: $1.53 per Share
  source text: At the Initial Closing, the Company has agreed to issue and sell 26,681,053 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $1.53 per Share (the “ Share Price ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm
- Equity Issuances
  Camp4 Therapeutics Corp issued pre-funded warrants to purchase 6,003,758 shares of Common Stock of warrant to certain accredited investors for $1.5299 per pre-funded warrant.
  - Security: warrant
  - Shares: pre-funded warrants to purchase 6,003,758 shares of Common Stock
  - Purchaser: certain accredited investors
  - Consideration: $1.5299 per pre-funded warrant
  source text: in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 6,003,758 shares of Common Stock (the “ Warrant Shares ” and, together with the Shares, the “ Securities ”) at an offering price of $1.5299 per pre-funded warrant (the “ Pre-Funded Warrant Price ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm
- Equity Issuances
  Camp4 Therapeutics Corp issued an additional 36,361 Shares of common stock to certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon for a purchase price of $1.65 per share.
  - Security: common stock
  - Shares: an additional 36,361 Shares
  - Purchaser: certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon
  - Consideration: a purchase price of $1.65 per share
  source text: the Company will issue and sell to certain members of management, including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young, who also serves as a director on the Company’s Board of Directors (the “ Board ”) and Leonard Zon, who serves as a Board observer, an additional 36,361 Shares at a purchase price of $1.65 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000072/0001736730-25-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.